Research Article

Treatment of perianal fistulae in crohn's disease with mesenchymal stem cells

Mohamed Hassin Mohamed Chairi*, Francisco José Huertas Peña, Marta Santidrián Zurbano, Tomás Torres Alcalá and Jesús María Villar del Moral

Published: 04 May, 2022 | Volume 6 - Issue 1 | Pages: 006-020

Crohn's disease is a chronic syndrome of the gastrointestinal tract that produces idiopathic inflammation. Approximately half of the patients develop abscesses and/or fistulas throughout their history that are located, mainly, in the perianal region. Current treatments are based on individualized plans that generally use combined pharmacology for symptomatic relief based on glucocorticoids, immunosuppressants or immunomodulators, antibiotics, anti-inflammatories, probiotics, and antibodies, or surgical therapies such as intestinal resections or ostomizations (colostomy and ileostomy) that tend to cause notable side effects in a considerable percentage of patients and a significant decrease in their quality of life.
Perianal fistulas consist of abnormal tracts, inflammatory tunnels, or chronic tracts of granular tissue that connect two surfaces lined with epithelium, have an external hole in the skin that borders the anus, and an internal hole located inside it around the anal canal, rectus and sphincters. 
Treatment is a complex process that requires a multidisciplinary approach and the combination of several treatments. In the short term, the goal is to drain abscesses, reduce inflammatory and infectious processes, guard the fistulous tract with seton or lax lines, facilitate patency, and hinder new formations. In the long term, a total cure and the avoidance of complications that require surgery or the creation of intestinal stomas are pursued.
For this reason, new effective remedies with fewer adverse effects continue to be investigated, one of the most promising being the use of mesenchymal stem cells for the regeneration and cure of perianal fistulas and the remission of symptoms. The present bibliographic review delves into this new therapy and analyzes the current state of the situation regarding its efficacy and safety.

Read Full Article HTML DOI: 10.29328/journal.acgh.1001033 Cite this Article Read Full Article PDF


  1. Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn's disease. Dis Mon. 2018 Feb;64(2):20-57. doi: 10.1016/j.disamonth.2017.07.001. Epub 2017 Aug 18. PMID: 28826742.
  2. Figueroa C. Epidemiología de la enfermedad inflamatoria intestinal. Rev Med Clin Las Condes. 2019;30(4):257-261. DOI: 10.1016/j.rmclc.2019.06.003.
  3. Bastida G, Garrido A, Valero E, del Pozo P. Enfermedad de Crohn. Medicine 2020;13(11):603-612.
  4. Veauthier B, Hornecker JR. Crohn's Disease: Diagnosis and Management. Am Fam Physician. 2018;98(11):661-669. PMID: 30485038.
  5. Ballester MP, Boscá-Watts MM, Mínguez M. Enfermedad de Crohn. Med Clin. 2018;151(1):26-33. Disponible en: https://www.sciencedirect.com/science/article/pii/S0025775317308448
  6. Lopez N, Ramamoorthy S, Sandborn WJ. Recent advances in the management of perianal fistulizing Crohn's disease: lessons for the clinic. Expert Rev Gastroenterol Hepatol 2019;13(6):563-577. DOI: 10.1080/17474124.2019.1608818.
  7. Grimstad T, Carlsen A, Karlsen LN. Medical management of fistulising Crohn's disease. Tidsskr Nor Laegeforen. 2019 Jan 9;139(1). English, Norwegian. doi: 10.4045/tidsskr.17.1055. PMID: 30644688.
  8. Vetter M, Neurath MF. Treatment Perspectives in Crohn's Disease. Digestion. 2018;98(3):135-142. doi: 10.1159/000488449. Epub 2018 Jun 5. PMID: 29870990.
  9. Xu M, Yang B, Chen H, Gu Y, Li Y. Analysis of Risk Factors for Anorectal Stenosis of Perianal Fistulizing Crohn's Disease. Med Sci Monit. 2020 Feb 28;26:e920243. doi: 10.12659/MSM.920243. PMID: 32109226; PMCID: PMC7063846.
  10. González N. Situación Actual en el Tratamiento de la Enfermedad de Crohn Perianal. Archivos de coloproctología 2019;2(2):4-33. DOI: https://doi.org/10.26754/ojs_arcol/arch_colo.201923794.
  11. Mao F, Tu Q, Wang L, Chu F, Li X, Li HS, Xu W. Mesenchymal stem cells and their therapeutic applications in inflammatory bowel disease. Oncotarget. 2017 Jun 6;8(23):38008-38021. doi: 10.18632/oncotarget.16682. PMID: 28402942; PMCID: PMC5514968.
  12. Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res Ther. 2016 Aug 31;7(1):125. doi: 10.1186/s13287-016-0363-7. PMID: 27581859; PMCID: PMC5007684.
  13. Assis-Ribas T, Forni MF, Winnischofer SMB, Sogayar MC, Trombetta-Lima M. Extracellular matrix dynamics during mesenchymal stem cells differentiation. Dev Biol. 2018 May 15;437(2):63-74. doi: 10.1016/j.ydbio.2018.03.002. Epub 2018 Mar 12. PMID: 29544769.
  14. Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine. Int J Mol Sci. 2017 Aug 25;18(9):1852. doi: 10.3390/ijms18091852. PMID: 28841158; PMCID: PMC5618501.
  15. Andrzejewska A, Lukomska B, Janowski M. Concise Review: Mesenchymal Stem Cells: From Roots to Boost. Stem Cells. 2019 Jul;37(7):855-864. doi: 10.1002/stem.3016. Epub 2019 Apr 30. PMID: 30977255; PMCID: PMC6658105.
  16. Naji A, Eitoku M, Favier B, Deschaseaux F, Rouas-Freiss N, Suganuma N. Biological functions of mesenchymal stem cells and clinical implications. Cell Mol Life Sci. 2019 Sep;76(17):3323-3348. doi: 10.1007/s00018-019-03125-1. Epub 2019 May 4. PMID: 31055643.
  17. Zuo W, Xie B, Li C, Yan Y, Zhang Y, Liu W, Huang J, Chen D. The Clinical Applications of Endometrial Mesenchymal Stem Cells. Biopreserv Biobank. 2018 Apr;16(2):158-164. doi: 10.1089/bio.2017.0057. Epub 2017 Dec 21. PMID: 29265881; PMCID: PMC5906727.
  18. Ryu JS, Jeong EJ, Kim JY, Park SJ, Ju WS, Kim CH, Kim JS, Choo YK. Application of Mesenchymal Stem Cells in Inflammatory and Fibrotic Diseases. Int J Mol Sci. 2020 Nov 7;21(21):8366. doi: 10.3390/ijms21218366. PMID: 33171878; PMCID: PMC7664655.
  19. Markov A, Thangavelu L, Aravindhan S, Zekiy AO, Jarahian M, Chartrand MS, Pathak Y, Marofi F, Shamlou S, Hassanzadeh A. Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders. Stem Cell Res Ther. 2021 Mar 18;12(1):192. doi: 10.1186/s13287-021-02265-1. PMID: 33736695; PMCID: PMC7971361.
  20. Mishra VK, Shih HH, Parveen F, Lenzen D, Ito E, Chan TF, Ke LY. Identifying the Therapeutic Significance of Mesenchymal Stem Cells. Cells. 2020 May 6;9(5):1145. doi: 10.3390/cells9051145. PMID: 32384763; PMCID: PMC7291143.
  21. Agencia Española de Medicamentos y productos Sanitarios. Informe de Posicionamiento Terapéutico de Darvadstrocel (Alofisel®) en el tratamiento de fístulas perianales complejas en enfermedad de Crohn. Ministerio de Sanidad, Consumo y Bienestar Social. 2019;50/2019 V1.
  22. Laureti S, Gionchetti P, Cappelli A, Vittori L, Contedini F, Rizzello F, Golfieri R, Campieri M, Poggioli G. Refractory Complex Crohn's Perianal Fistulas: A Role for Autologous Microfragmented Adipose Tissue Injection. Inflamm Bowel Dis. 2020 Jan 6;26(2):321-330. doi: 10.1093/ibd/izz051. PMID: 31220252; PMCID: PMC6943693.
  23. Carvello M, Lightner A, Yamamoto T, Kotze PG, Spinelli A. Mesenchymal Stem Cells for Perianal Crohn's Disease. Cells. 2019 Jul 23;8(7):764. doi: 10.3390/cells8070764. PMID: 31340546; PMCID: PMC6679174.
  24. Zhang J, Lv S, Liu X, Song B, Shi L. Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease: A Randomized Controlled Clinical Trial. Gut Liver. 2018 Jan 15;12(1):73-78. doi: 10.5009/gnl17035. PMID: 28873511; PMCID: PMC5753687.
  25. Lightner AL, Wang Z, Zubair AC, Dozois EJ. A Systematic Review and Meta-analysis of Mesenchymal Stem Cell Injections for the Treatment of Perianal Crohn's Disease: Progress Made and Future Directions. Dis Colon Rectum. 2018 May;61(5):629-640. doi: 10.1097/DCR.0000000000001093. PMID: 29578916.
  26. Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Diez MC, Tagarro I, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients with Crohn's Disease. Gastroenterology 2018 [citado 10 abr 2021];154(5):1334-1342. DOI: 10.1053/j.gastro.2017.12.020.
  27. Barnhoorn MC, Wasser MNJM, Roelofs H, Maljaars PWJ, Molendijk I, Bonsing BA, Oosten LEM, Dijkstra G, van der Woude CJ, Roelen DL, Zwaginga JJ, Verspaget HW, Fibbe WE, Hommes DW, Peeters KCMJ, van der Meulen-de Jong AE. Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas. J Crohns Colitis. 2020 Jan 1;14(1):64-70. doi: 10.1093/ecco-jcc/jjz116. PMID: 31197361; PMCID: PMC6930001.
  28. Dige A, Hougaard HT, Agnholt J, Pedersen BG, Tencerova M, Kassem M, Krogh K, Lundby L. Efficacy of Injection of Freshly Collected Autologous Adipose Tissue Into Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology. 2019 Jun;156(8):2208-2216.e1. doi: 10.1053/j.gastro.2019.02.005. Epub 2019 Feb 14. PMID: 30772343.
  29. Molendijk I, Bonsing BA, Roelofs H, Peeters KC, Wasser MN, Dijkstra G, van der Woude CJ, Duijvestein M, Veenendaal RA, Zwaginga JJ, Verspaget HW, Fibbe WE, van der Meulen-de Jong AE, Hommes DW. Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology. 2015 Oct;149(4):918-27.e6. doi: 10.1053/j.gastro.2015.06.014. Epub 2015 Jun 25. PMID: 26116801.
  30. Ko JZ, Johnson S, Dave M. Efficacy and Safety of Mesenchymal Stem/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review. Biomolecules. 2021 Jan 11;11(1):82. doi: 10.3390/biom11010082. PMID: 33440772; PMCID: PMC7827559.


Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?